Know Cancer

forgot password

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

Phase 2
18 Years
70 Years
Open (Enrolling)
Advanced Primary Lung Adenocarcinoma

Thank you

Trial Information

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

Inclusion Criteria:

- Histologically or cytologically newly diagnosed as unresectable and metastasis
advanced lung adenocarcinoma(Stage IV, Seventh Edition of the UICC/AJCC
Classification for Lung Cancer).

- At least one measurable objective tumor lesion, spiral CT or PET-CT examination: the
shortest diameter ≥2cm,and no obvious necrosis

- Life expectancy ≥12weeks

- Patients receive palliative radiotherapy for bone's pain relief; patients receive
radiotherapy for brain metastasis、patients after brain transfer operation or
radiation therapy are allowed to enter the research.

- 18≤Patients'age <70 years.

- Electrocolonogram (ECOG) Score:0-1.

- Granulocyte count ≥ 2.0×109/L, platelet count ≥ 100×109/L.

- Serum bilirubin within the normal range.

- Aspartate aminotransferase ( AST ), Alanine aminotransferase ( ALT ) within the
normal range(if the patients is diagonosed as liver metastasis,his/her AST/ALT should
not surpass 1.5 times of the normal range ).

- Serum creatinine within the normal range and creatinine clearance rate ≥60ml/min

- Compliance with research requirements and be able to follow up.

- Within 72 hours before the treatment, all women pregnant with pregnant possibility
should undergo pregnancy test and get negative results.

- Patients with fertility ability should take effective contraceptive techniques.

- Sign informed consent of this clinic trial.

Exclusion Criteria:

- Lung adenocarcinoma patients who received systemic chemotherapy/thoracic
radiotherapy/targeted therapy

- Received resection, cutting or aspiration within seven days

- Any unstable systemic diseases (including peptic ulcer、active infection、grade4
hypertension、unstable angina、congestive heart failure、liver, metabolic disorders or
fracture、unhealing wound )

- Chronic kidney disease history(including chronic nephritis, nephrotic syndrome,
Obstruction of urinary tract etc. caused by Urinary calculus)

- have to use anticoagulant drugs at the same time

- patients with obvious coagulation disorders、active bleeding and bleeding tendency

- Any other malignancies (complete cure of cervical carcinoma in situ/basal cell
carcinoma/squamous cell carcinoma are excluded )happened within 5 years.

- Signifinant weight loss, weight lost during the 6 weeks more than or equal to 10%

- Patients who take bone metastasis as the only observing index

- Allergic to escherichia coli preparation

- Used Endostar before

- Lactating women

- Contraindications written on Pemetrexed、Carboplatin、Dexamethasone instructions

- Allergic to radiographic contrast agents

- In the middle or planning to attend other clinic trails

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

the change of blood perfusion before/after the use of Endostar

Outcome Time Frame:

per 3 weeks

Safety Issue:



China: Ethics Committee

Study ID:




Start Date:

March 2012

Completion Date:

July 2013

Related Keywords:

  • Advanced Primary Lung Adenocarcinoma
  • endostar
  • CT Perfusion
  • Advanced Primary Lung Adenocarcinoma
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Lung Neoplasms